Last reviewed · How we verify
Fml (FLUOROMETHOLONE)
Fml (FLUOROMETHOLONE) is a corticosteroid medication developed by Allergan and currently owned by Abbvie. It targets the glucocorticoid receptor to reduce inflammation in the eye. Fml is approved to treat various ocular conditions, including allergic conjunctivitis, corneal abrasions, and post-operative ocular inflammation. The medication is available as a generic product, off-patent, with multiple manufacturers. Key safety considerations include potential increased intraocular pressure and cataract formation.
At a glance
| Generic name | FLUOROMETHOLONE |
|---|---|
| Sponsor | AbbVie |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1972 |
Approved indications
- Steroid-responsive ocular inflammation
Common side effects
- Delayed wound healing
- Systemic hypercorticoidism
- Acute anterior uveitis
- Perforation of the globe
- Keratitis
- Conjunctivitis
- Corneal ulcers
- Mydriasis
- Conjunctival hyperemia
- Loss of accommodation
- Ptosis
- Secondary ocular infection
Key clinical trials
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- Fluorometholone Study (PHASE2)
- The OPTIMISE Study (PHASE4)
- Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease (PHASE4)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea (PHASE4)
- Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fml CI brief — competitive landscape report
- Fml updates RSS · CI watch RSS
- AbbVie portfolio CI